Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Virbac : operating profit from ordinary activities 2017 comparable to 2016


Posted on: 14 Mar 18

Virbac: operating profit from ordinary activities 2017 comparable to 2016

Public release dated March 14, 2018

CONSOLIDATED DATA AS OF
DECEMBER 31st
in € million 
  2017 2016 % change 2017/2016  
Revenue from ordinary activities 861.9 871.8 -1.1%  
Evolution at constant exchange rates     -0.5%  
Evolution at constant exchange rates and scope 1     -0.5%  
Current operating profit before depreciation of assets arising from acquisitions 2 80.3 82.9 -3.0%  
As a % of sales
As a % of sales at constant exchange rates
9.3%
9.3%
9.5%    
Depreciations of intangibles assets arising from acquisitions 15.9 16.5    
Operating profit from ordinary activities 64.4 66.4 -3.0%  
Non-recurring expenses and revenues 6.3 -2.6    
Operating profit 58.0 69.0 -15.9%  
Net profit from ordinary activities 3 29.5 35.2 -16.3%  
Net consolidated profit 1.8 37.9 -95.4%  
Of which net profit - Group share -2.6 34.6 -107.4%  
Shareholder's equity 436.3 473.6 -7.9%  
Net debt 4 460.0 547.1 -15.9%  
Operating cash flow 5 106.8 110.7 -3.6%  

1 Evolution at constant exchange rates and scope is the organic growth of sales, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and that for the previous financial year on the basis of identical exchange rates (the exchange rate used is that in effect for the previous financial year), and excluding the impact of changes in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year
2 Current operating profit before depreciation of assets arising from acquisitions reflects profit from ordinary activities adjusted for the impact of allowances for depreciation of intangible assets resulting from acquisition transactions
3 Net profit from ordinary activities corresponds to net consolidated profit adjusted for non-recurring expenses and income (€6.3 million), and for non-current tax (€21.4 million)
4 Net debt corresponds to current (€98.8 million) and non-current (€409.6 million) financial liabilities less cash and cash equivalents (€48.4 million) as published in the statement of financial position
5 Operating cash flow corresponds to operating profit (€58.0 million) adjusted for items without any impact on cash position. The following items are adjusted: asset depreciation and impairments (€42.8 million), provisions for risks (€0.7 million), provisions related to employee benefits (€0.0 million), and the other expenses and income without any impact on cash position (€5.3 million)

 The accounts were audited; the statutory auditor's report is in the process of being issued. They are available on the corporate site at corporate.virbac.com.

The Group registered annual revenue of €861.9 million, a slight decline of -1.1% and -0.5% at actual exchange rates and constant rates respectively, compared to last year. From a regional perspective, growth has been strong outside of the United States, at 3.4% and 3.6% at comparable rates. In Europe, there has been slight growth at constant exchange rates, boosted by the performance of the United Kingdom, Italy, Poland and Belgium, despite an overall downturn in the vaccine and external parasiticide ranges. In the rest of the world, organic growth continues to be strong in many emerging countries, in particular Brazil, Mexico, Chile, China, as well as India, which returned to two-digit growth in the second half of the year after the effects of the coming into force of the new VAT in mid 2017, as well as demonetization at the end of 2016. The Pacific region showed a slight decline over the year, primarily as a result of a decision to discontinue products in New Zealand. Finally, business recovery has been slower than expected in the United States, posting a drop in business of -20.2% at constant exchange rates.

Current operating profit before depreciation of assets arising from acquisitions amounted to €64.4 million, slightly down from 2016 (€66.4 million), despite increased investment in R&D compared to 2016 (+€5.6 million at constant rates). Exchange rates had a very slight negative impact on operating profit adjusted in the amount of +€0.3 million. Operating profit from ordinary activities benefited from strong performance in a number of countries, including Brazil, Mexico, Chile, China, and India, as well as from sound cost control. This performance was offset by weaker activity recorded in the United States, which adversely affected the cost of sales, as well as the increased investment in R&D.

Net profit from ordinary activities (net consolidated profit adjusted for non-recurring expenses and income and for non-current tax) totaled €29.5 million, down 16.3% from 2016. Net profit from ordinary activities was impacted by decreased activity, higher financing costs associated with a less favorable exchange rate impact on the Chilean Peso compared to 2016, as well as by an increase in the current tax expense.

 Net profit - Group share was -€2.6 million, a significant drop compared to the previous year, in particular as a result of the impairment of the deferred tax asset on tax losses carried forward by the US subsidiary from the 2015 to 2017 financial years (€21.4 million). This impairment is explained, in application of IAS12, in particular by the existence of a history of recent and unused tax losses. The decrease in net result is also explained to a lesser extent by the €5 million impairment of the assets associated with the leishmaniosis vaccine, following the arrival of a new player on the market.

From a financial standpoint, the Group's net debt is at €460 million, down by €87 million compared to December 31, 2016. The lack of a dividend payment by Virbac SA on 2016 profits, a strict monitoring of working capital requirements, as well as further development of operating funding solutions (factoring in certain subsidiaries) contributed to the Group's debt relief. Furthermore, the positive euro-dollar exchange rate effect, which amounted to approximately €40 million, contributed to debt reduction. Thus, the Group is in compliance with the financial ratio (Net debt/Ebitda), which amounts to 4.28 versus 4.75, the maximum limit set at the end of December, 2017 as part of the financial covenant.

Outlook

Given the slower than expected business recovery in the United States, and thanks to a performance that the Group is forecasting to be rather good in the other regions, a low-single-digit increase in revenue at constant rates is expected in 2018 compared to 2017.

For the entire year, the Group anticipates the ratio of "current operating profit before depreciation of assets arising from acquisitions" to "revenue", at constant exchange rates, will increase by around 0.5 point compared to 2017.

From a financial standpoint, tight control of invested capital should allow further debt relief, which is expected to hover around €30 million for the year. Furthermore, as part of its funding policy, the Group strengthened its liquidity through establishment of a medium-to-long-term line of credit of up to $90 million. This new line thus completes the RCF line (Revolving credit facility) of €420 million, signed in 2015 with historical banking pool, bilateral lines and outstanding Schuldschein loans. Similarly, in order to afford itself greater flexibility, the Group obtained a relaxation of its financial covenant (net debt/Ebitda) with its bankers for 2018. It was set at 5.0 at the end of June 2018 versus 5.5 at the end of June 2017, and at 4.25 at the end of December 2018 versus 4.75 at the end of December 2017. As of 2019, it will return to the initial commitment levels of 4.25 at the end of June and 3.75 at the end of December.

ANALYSTS' PRESENTATION - VIRBAC

Virbac will hold an analysts' meeting on Monday, March 19, 2018 at 2:30 pm CET (Paris time) in the New York Room #Cloud Business Center, 10 bis, rue du 4 Septembre, 75002 in Paris (France).

Participants may arrive 15 minutes before the start of the meeting.

You may also attend the meeting using the webcast available via the link below.

Information for participants

Webcast access link: https://lc.cx/Aryj

This access link is available on the site corporate.virbac.com, under the heading ''financial public releases''. This link allows participants to access the live and/or archived version of the webcast.

There will be no real-time interaction. You may send us your questions, if necessary, via our email address: finances@virbac.com.

A LABORATORY THAT HAS ALWAYS BEEN DEDICATED TO ANIMAL HEALTH
Virbac offers veterinarians, farmers and pet owners in more than 100 countries a comprehensive and practical range of products and services. With these innovative solutions covering the majority of animal species and diseases, Virbac contributes, day after day, to shape the future of animal health.

Virbac: NYSE Euronext - compartment B - ISIN code: FR0000031577/SYMBOL: VIRP
Corporate finance: +33 4 92 08 71 32 - finances@virbac.com - corporate.virbac.com

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/351e9143-b408-4213-8012-049bfd883c93

GlobeNewswire
globenewswire.com

Last updated on: 15/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.